BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/8/2023 9:38:25 AM | Browse: 138 | Download: 375
 |
Received |
|
2023-06-20 07:35 |
|
Peer-Review Started |
|
2023-06-20 07:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-07-07 07:19 |
|
Revised |
|
2023-07-12 13:46 |
|
Second Decision |
|
2023-08-11 02:36 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-08-11 08:06 |
|
Articles in Press |
|
2023-08-11 08:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-08-29 02:36 |
|
Publish the Manuscript Online |
|
2023-09-08 09:38 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li Zheng, Li-Hong Gan, Ling Yao, Bin Li, Ya-Qin Huang, Fu-Bao Zhang, Meng-Qi Kuang and Nian Fang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Jiangxi Province Major Discipline Academic and Technical Leaders Project |
812178084229 |
|
| Corresponding Author |
Nian Fang, PhD, Doctor, Doctor, Department of Gastroenterology, The First Hospital of Nanchang, No. 128 Xiangshan North Road, Nanchang 330008, Jiangxi Province, China. zl13870673345@163.com |
| Key Words |
FLOT regimen; SOX regimen; Advanced gastric cancer; First-line chemotherapy; Tissue peptide-specific antigen |
| Core Tip |
The prognosis of HER2-positive gastric cancer patients is generally worse; hence, there is an urgent need to explore new and effective treatments. Gastric cancer is a common malignant tumor disease in the digestive system. Cumulative data suggests that the incidence rate of gastric cancer ranks second among all malignant tumors, and the mortality rate ranks third. Furthermore, there is a rising trend in the incidence rate, which poses a serious threat to the physical and mental health of the population. The rapid development of modern medical technology has promoted the emergence of targeted therapy in clinical practice. However, due to the heterogeneous and complex nature of gastric cancer progression, its application is limited and the progress is slow. |
| Publish Date |
2023-09-08 09:38 |
| Citation |
Zheng L, Gan LH, Yao L, Li B, Huang YQ, Zhang FB, Kuang MQ, Fang N. Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer. World J Clin Cases 2023; 11(26): 6083-6090 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i26/6083.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i26.6083 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
